
Conference Coverage
about 2 months ago
Neoadjuvant SAbR shows promising outcomes in RCC with tumor thrombusabout 2 months ago
Mark Tyson, MD shares promising BOND-003 results in papillary NMIBCabout 2 months ago
Cretostimogene demonstrates safety, efficacy in papillary NMIBC cohortabout 2 months ago
SYNC-T demonstrates high bone metastasis resolution in phase 1 cohortabout 2 months ago
CORE-008: Cretostimogene achieves high CR rate in high-risk NMIBCabout 2 months ago
NDV-01 produces robust 9-month results in high-risk NMIBCLatest News

Pearls & Perspectives: Innovation, Education, and the Future of Pelvic Floor Care, With Katherine Amin, MD, FPMRS, FACS, FRCS

FDA premarket approval sought for Signatera CDx test in MIBC

FDA updates in urology: January 2026

Trial to compare 225Ac-PSMA-617 vs 177Lu-PSMA-617 for oligorecurrent prostate cancer

Pearls & Perspectives: Innovation and Evolving Pathways in Female Pelvic Medicine, with Raveen Syan, MD, FPMRS

Shorts










Podcasts
Videos
Urology Times Digital Edition







Continuing Medical Education
All News

Cooled laser focal therapy with the ProFocal Device showed promising cancer control in patients with localized prostate cancer.

In this episode, Amy Pearlman, MD, speaks with Phillip M. Pierorazio, MD, about integrating mindfulness and wellness into a demanding surgical career and the evolving complexities of modern prostate cancer care.

The combination was tolerable and demonstrated promising early efficacy as a 3rd-line option for patients with mCRPC.

Beyond operative technique, the episode addresses patient counseling, including expectations around fertility, anejaculation, and postoperative complications such as chyle leak.

The report highlights key trends in cancer treatment and outcomes, including detailed analyses across 3 cancer types: prostate, esophageal, and melanoma.

AVA-291 is a differentiated formulation of testosterone designed to retain androgen activity while resisting aromatization.

Gonzalgo explores how prostate cancer diagnosis and management continue to evolve.


The prospective registry is evaluating a personalized counseling and monitoring strategy for patients who are at an increased risk of prostate cancer due to positive family history or pathogenic genetic variants.

In this episode of Pearls and Perspectives, host Amy Pearlman, MD, sits down with Ariana L. Smith, MD, to explore how clinicians navigate evidence gaps, evolving guidelines, and emerging innovation in overactive bladder care.

The results highlight the early clinical potential of the device for restoring erectile function post-prostatectomy.

The safety and efficacy of the Break Wave device was assessed in the pivotal SOUND trial.

The ARID platform is evaluating the safety and efficacy of the Voro Urologic Scaffold in minimizing stress urinary incontinence following robot-assisted radical prostatectomy.

The phase 3 BiPASS trial is assessing earlier use of 68Ga-PSMA-PET imaging in the pre-biopsy setting.

Enrollment in the ongoing pivotal QUILT-2.005 trial has now reached 85%.




























